Wells Fargo & Company Neurocrine Biosciences Inc Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Wells Fargo & Company holds 260,415 shares of NBIX stock, worth $30.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

260,415

Previous 234,969 10.83%

Holding current value

$30.6 Million

Previous $32.3 Million 7.32%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $2.92 Million - $3.9 Million	25,446 Added 10.83%	260,415 $30 Million
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $1.72 Million - $1.88 Million	13,155 Added 5.93%	234,969 $32.3 Million
Q1 2024 May 10, 2024	BUY	$130.4 - $143.74 $15.5 Million - $17.1 Million	118,786 Added 115.29%	221,814 $30.6 Million
Q4 2023 Feb 09, 2024	SELL	$106.07 - $132.76 $476,572 - $596,490	-4,493 Reduced 4.18%	103,028 $13.6 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $446,406 - $555,990	4,748 Added 4.62%	107,521 $12.1 Million
Q2 2023 Aug 15, 2023	BUY	$89.53 - $104.87 $1.03 Million - $1.21 Million	11,559 Added 12.67%	102,773 $9.69 Million
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $91,192 - $119,206	969 Added 1.07%	91,214 $9.23 Million
Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $266,800 - $317,650	2,500 Added 2.85%	90,245 $10.8 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $214,798 - $251,628	-2,334 Reduced 2.59%	87,745 $9.32 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $1.04 Million - $1.37 Million	-13,684 Reduced 13.19%	90,079 $8.78 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $832,812 - $1.09 Million	11,495 Added 12.46%	103,763 $9.73 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $15.9 Million - $21.2 Million	-199,713 Reduced 68.4%	92,268 $7.86 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $7.11 Million - $8.17 Million	-82,475 Reduced 22.03%	291,981 $28 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $6.32 Million - $7.22 Million	70,615 Added 23.24%	374,456 $36.4 Million
Q1 2021 May 13, 2021	SELL	$87.57 - $119.4 $1.87 Million - $2.56 Million	-21,408 Reduced 6.58%	303,841 $29.5 Million
Q4 2020 Feb 09, 2021	BUY	$86.91 - $108.33 $1.9 Million - $2.37 Million	21,837 Added 7.2%	325,249 $31.2 Million
Q3 2020 Nov 05, 2020	BUY	$96.16 - $135.15 $2.15 Million - $3.03 Million	22,387 Added 7.97%	303,412 $29.2 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $3.3 Million - $5.05 Million	38,758 Added 16.0%	281,025 $34.3 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $18.2 Million - $27.6 Million	242,267 New	242,267 $21 Million

Others Institutions Holding NBIX

# of Institutions

623

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Neurocrine Biosciences Inc Transaction History